Literature DB >> 30821385

Updates in cutaneous lymphoma: evidence-based guidelines for the management of cutaneous lymphoma 2018.

Y Wang1, M Bagot2.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 30821385     DOI: 10.1111/bjd.17523

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  3 in total

Review 1.  Cutaneous T cell lymphoma.

Authors:  Reinhard Dummer; Maarten H Vermeer; Julia J Scarisbrick; Youn H Kim; Connor Stonesifer; Cornelis P Tensen; Larisa J Geskin; Pietro Quaglino; Egle Ramelyte
Journal:  Nat Rev Dis Primers       Date:  2021-08-26       Impact factor: 52.329

2.  Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Authors:  P Quaglino; H M Prince; R Cowan; M Vermeer; E Papadavid; M Bagot; O Servitjie; E Berti; E Guenova; R Stadler; C Querfeld; A M Busschots; E Hodak; A Patsatsi; J Sanches; M Maule; J Yoo; M Kevin; P Fava; S Ribero; L Zocchi; M Rubatto; M T Fierro; U Wehkamp; M Marshalko; C Mitteldorf; O Akilov; P Ortiz-Romero; T Estrach; L Vakeva; P A Enz; M Wobser; M Bayne; C Jonak; M Rubeta; A Forbes; A Bates; M Battistella; R Amel-Kashipaz; B Vydianath; A Combalia; E Georgiou; E Hauben; E K Hong; M Jost; R Knobler; I Amitay-Laish; D Miyashiro; J Cury-Martins; X Martinez; C Muniesa; H Prag-Naveh; A Stratigos; V Nikolaou; K Quint; C Ram-Wolff; K Rieger; R Stranzenbach; Á Szepesi; S Alberti-Violetti; E Felicity; L Cerroni; W Kempf; S Whittaker; R Willemze; Y Kim; J J Scarisbrick
Journal:  Br J Dermatol       Date:  2021-02-18       Impact factor: 9.302

3.  Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System.

Authors:  Gabriele Roccuzzo; Silvia Giordano; Gianluca Avallone; Marco Rubatto; Silvia Canonico; Ada Funaro; Erika Ortolan; Rebecca Senetta; Paolo Fava; Maria Teresa Fierro; Simone Ribero; Pietro Quaglino
Journal:  Cells       Date:  2022-01-20       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.